Compare CVS Health Corp (CVS) vs ThredUp Inc (TDUP) Price & Performance

CVS Health trades at $86.16, down 2.04% for the day, amid a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.58 exceeding the $1.85 estimate. Revenue grew to $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst consensus is overwhelmingly positive, with 35 of 41 analysts rating the stock a Buy and a consensus price target of $111.20, implying significant upside. Recent news highlights Aetna's 2027 Medicare plan updates and a quarterly dividend declaration.

The outlook for CVS remains favorable based on fundamental strength and analyst optimism, but risks include reimbursement pressure, regulatory scrutiny, and a high debt load. The stock's current valuation metrics, such as a P/E of 23.17 and P/S of 0.27, appear reasonable relative to historical levels, supporting a constructive view for long-term investors despite near-term technical weakness.

ThredUp (TDUP) trades at $2.455, up 10.59% in the past 24 hours, with a bearish technical signal but strong analyst support. The company reported record Q2 2026 revenue of $90.8 million, up 17% year-over-year, but missed earnings expectations with a net loss. Fundamentals show a high gross margin of 79.52% but negative net income margin and ROE, while cash flow from operations improved to $10.65 million in 2025.

The outlook is mixed: analyst consensus is 57% buy with no sell ratings, but profitability remains a challenge amid promotional headwinds. Risks include ongoing losses, competitive pressures, and a recent stock decline following guidance cuts. Investment opportunity hinges on execution toward profitability despite current bearish technicals.